ESR2 and neoplasm: Our previous cancer-related study shows that the ERβ-specific agonist S-equol elevates the same phosphotyrosine switch in cancer cells and antitumor CD8+ T cells and inhibits tumor growth in both xenograft and syngeneic tumor models (Yuan et al., 2016, 2021).